Lisdexamfetamine Dimesylate Capsule
Product Images NDC 72162-2454

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Lisdexamfetamine Dimesylate (NDC 72162-2454). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721622454)

This text is a package insert for Lisdexamfetamine 30 mg capsules, also known as dimesylate. It contains important information including the NDC code, manufacturer details, storage instructions, and dosage information accessible via a QR code on the package. Pharmacists are advised to dispense the medication guide to each patient. Storage at room temperature and in a light-resistant container is recommended. The medication should be kept out of reach of children.*

FDA Label Image

Chemical Structure (Lisdexcaps 01)

FDA Label Image

Figure 1 (Lisdexcaps 02)

This text provides information related to special populations, specifically focusing on gender (Male/Female) and age (65 years to less than 75 years). It also mentions different levels of renal impairment: Mild, Moderate, Severe, and End Stage Renal Disease. Additionally, there is a reference to Fold Change and a 90% Confidence Interval (CI) in the context of alteration in values compared to a reference.*

FDA Label Image

Figure 2 (Lisdexcaps 03)

This text appears to be a brief list of pharmaceutical substances (Guanfacine, Venlafaxine, Omeprazole) with associated measurements such as Cmax and AUC. It also mentions fold change and 90% CI, indicating a calculation or comparison related to these substances. The text might be detailing changes or differences observed in these substances in a study or experiment.*

FDA Label Image

Figure 3 (Lisdexcaps 04)

The text provided includes a list of different drugs classified as substrates for various CYP enzymes. It also mentions pharmacokinetic parameters such as Cmax and AUC, along with fold change and 90% confidence intervals. The data may be part of a drug interaction study or pharmacological evaluation.*

FDA Label Image

Figure 4 (Lisdexcaps 05)

This text shows LS Mean (SE) SKAMP Deportment Scores for Placebo and Lisdexamfetamine at different time points post-dose (0, 2, and 5 hours). These scores indicate the level of deportment or behavior observed in the study participants.*

FDA Label Image

Figure 5 (Lisdexcaps 06)

FDA Label Image

Figure 6 (Lisdexcaps 07)

This text provides data on LS Mean (SE) PERMP Total Scores of Lisdexamfetamine over time post-dose in hours. The scores range from 250 to 330, with specific values at different time points. The information seems to be part of a study or analysis related to the impact of Lisdexamfetamine on PERMP Total Scores over a period of time.*

FDA Label Image

Figure 7 (Lisdexcaps 08)

This text shows information about the proportion of subjects with relapse or treatment failure expressed as a percentage for lisdexamfetamine at different time points following randomization. Data points for days after randomization are also given.*

FDA Label Image

Figure 8 (Lisdexcaps 09)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.